Clinical Studies Sponsored by Neurocrine Biosciences

A Study to Evaluate NBI-6024 in Adult and Adolescent Patients With New Onset of Type 1 Diabetes Mellitus

Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)

An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

Opicapone Treatment Initiation Open-Label Study

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia

A Study to Evaluate the Relative Bioavailability (BA) and Effect of Food on TAK-831 Tablet Formulations in Healthy Participants

Study to Determine D-amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-dose Oral Administration

Phase 1 Study of TAK-831 in Healthy Adult Asian Subjects

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants